EDITORIAL

EBMH Notebook

Are all antidepressants equal?

G Gartlehner^1,2, B N Gaynes³

¹ Danube University, Department for Evidence-based Medicine and Clinical Epidemiology, Krems, Austria
² Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, USA
³ Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA

Correspondence to:
^{Correspondence to} Dr G Gartlehner, Danube University, Department for Evidence-based Medicine and Clinical Epidemiology, Krems, Austria; gerald.gartlehner@donau-uni.ac.at

The first 150 words of the full text of this article appear below.

Primary care physicians and psychiatrists manage the majority of patients suffering from acute phase major depressive disorder (MDD). For most patients, antidepressant treatment is the primary choice of care. Second generation antidepressants (SGAs)—developed following the first generation of tricyclic and monoamine oxidase agents—have become the preferred drug choice because of their greater tolerability, lower risk of lethality and similar efficacy compared with first generation agents.

Clinicians prescribing SGAs face a multitude of drug choices and are the target of extensive marketing campaigns by the pharmaceutical industry. In 2007, three of the 20 top selling drugs in the USA were antidepressants with annual sales ranging from $2.3 billion (venlafaxine XR (Effexor XR)) to $1.4 billion (duloxetine (Cymbalta)).¹ At the time of writing, 13 different SGAs have been approved for the treatment of major depression in the USA and Canada and two additional drugs (reboxetine, milnacipran) are available in some . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?

Corrado Barbui, Andrea Cipriani, Toshiaki A Furukawa, Georgia Salanti, Julian P T Higgins, Rachel Churchill, Norio Watanabe, Atsuo Nakagawa, Ichiro M Omori, John R Geddes
Evid. Based Ment. Health 2009 12: 101-104. (in EBMH notebook) [Extract] [Full Text] [PDF]

Review: clinically important differences between antidepressants

R Hamish McAllister-Williams
Evid. Based Ment. Health 2009 12: 107. (in Therapeutics) [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Barbui, C., Cipriani, A., Furukawa, T. A, Salanti, G., Higgins, J. P T, Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M, Geddes, J. R (2009). Making the best use of available evidence: the case of new generation antidepressants: A response to: Are all antidepressants equal?. Evid. Based Ment. Health 12: 101-104 [Full Text]